Guardant Health Inc’s filing revealed that its Director Tariq Musa unloaded Company’s shares for reported $5606.0 on Feb 20 ’25. In the deal valued at $48.33 per share,116 shares were sold. As a result of this transaction, Tariq Musa now holds 3,078 shares worth roughly $0.12 million.
Then, Tariq Musa bought 116 shares, generating $5,606 in total proceeds.
Before that, Tariq Musa sold 116 shares. Guardant Health Inc shares valued at $4,359 were divested by the Director at a price of $37.58 per share. As a result of the transaction, Tariq Musa now holds 2,944 shares, worth roughly $0.12 million.
Barclays initiated its Guardant Health Inc [GH] rating to an Overweight in a research note published on January 23, 2025; the price target was $60. A number of analysts have revised their coverage, including Guggenheim’s analysts, who increased its forecast for the stock in late June from “a Neutral” to “a Buy”.
Price Performance Review of GH
On Tuesday, Guardant Health Inc [NASDAQ:GH] saw its stock fall -4.92% to $40.35. Over the last five days, the stock has lost -16.41%. Guardant Health Inc shares have risen nearly 32.08% since the year began. Nevertheless, the stocks have risen 78.07% over the past one year. While a 52-week high of $50.89 was reached on 01/30/25, a 52-week low of $15.81 was recorded on 01/02/25. SMA at 50 days reached $40.28, while 200 days put it at $30.71.
Levels Of Support And Resistance For GH Stock
The 24-hour chart illustrates a support level at 39.08, which if violated will result in even more drops to 37.82. On the upside, there is a resistance level at 42.81. A further resistance level may holdings at 45.28. The Relative Strength Index (RSI) on the 14-day chart is 39.81, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -3.61, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 99.27%. Stochastics %K at 7.35% indicates the stock is a buying.
The most recent change occurred on December 14, 2023 when Guggenheim began covering the stock and recommended ‘”a Neutral”‘ rating .
